| 曲建昌,王彤,李丽,等.维格列汀联合二甲双胍对超重2型糖尿病病人代谢指标的影响[J].安徽医药,2019,23(4):819-822. |
| 维格列汀联合二甲双胍对超重2型糖尿病病人代谢指标的影响 |
| Effect of vildagliptin combined with metformin on metabolic index in patients with overweight type 2 diabetes |
| 投稿时间：2017-03-21 |
| DOI： |
| 中文关键词: 糖尿病,2型 二甲双胍 血红蛋白A,糖基化 半胱氨酸 超重 维格列汀 |
| 英文关键词: Diabetes mellitus, type 2 Metformin Hemoglobin A,glycosylated Cysteine Overweight Vildagliptin |
| 基金项目: |
|
| 摘要点击次数: 2653 |
| 全文下载次数: 506 |
| 中文摘要: |
| 目的 观察维格列汀与二甲双胍联合应用对超重2型糖尿病病人代谢指标的综合影响,评价其疗效。方法 选取2013年12月至2016年10月中国人民解放军第三〇五医院收治单独应用二甲双胍(500 mg,3次/天,服用3个月以上)血糖控制不佳的超重2型糖尿病病人120例,按随机数字表法分为观察组(60例)和对照组(60例)。对照组口服二甲双胍剂量增加至1 000 mg、2次/天；观察组予口服二甲双胍500 mg、3次/天,并联用维格列汀50 mg、2次/天,共24周。比较治疗前后体质量指数(BMI)、糖化血红蛋白(HbA1c)、空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、总胆固醇(TC)、三酰甘油(TG) 和低密度脂蛋白胆固醇(LDL-C)、同型半胱氨酸(Hcy)等指标的变化。结果 治疗24周后,对照组FBG、2 h PBG、HbA1c分别为(7.98±0.83)mmol/L、(12.25±0.90)mmol/L、(8.05±1.05)%,观察组分别为(7.09±0.80) mmol/L、(9.86±1.13)mmol/L、(7.01±0.88)%,两组FBG、2 h PBG、HbA1c 均较治疗前降低(P＜0.05),观察组较对照组下降更明显(t值分别为:2.47、5.27、3.22,均P＜0.05)；治疗24周后,对照组BMI、TC、TG、LDL-C、Hcy分别为(27.60±3.70) kg/m2、(6.39±0.89) mmol/L、(2.77±0.40) mmol/L、(3.29±0.43) mmol/L、(17.4±2.03) mmol/L,观察组分别为(26.34±3.83) kg/m2、(5.31±0.72) mmol/L、(2.31±0.33) mmol/L、(2.92±0.44) mmol/L、(15.16±1.74) mmol/L,与治疗前比较,两组BMI、血脂、Hcy水平均显著下降(P＜0.05),观察组下降更显著(t值分别为:2.14、3.50、2.26、2.21、3.27,均P＜0.05)。两组不良反应发生率差异无统计学意义(χ2=2.62,P＞0.05)。结论 维格列汀联合二甲双胍能够有效控制肥胖或超重的2型糖尿病病人的血糖及BMI,并且能够改善血脂,降低血糖,且不增加低血糖风险,是超重或肥胖2型糖尿病病人有效治疗方案之一。 |
| 英文摘要: |
| Objective To observed the effect of vildagliptin and metformin on metabolic index in patients with overweight type 2 diabetes,and to evaluate its curative effect.Methods One hundred and twenty patients with overweight type 2 diabetes mellitus with poor blood sugar control in The 305 Hospital of PLA from December 2013 to October 2016 were treated with metformin alone (dose of 500 mg,3 / d,taking more than 3 months).The patients were assigned into observation group (60 cases) and control group (60 cases) by random number table method.Control group was given oral metformin (1 000 mg,2 times/d),while observation group was given oral metformin (500 mg,3 times/d) combined with vildagliptin (50 mg,2 times/d) for 24 weeks.The body mass index (BMI) before and after the treatment,glycated hemoglobin (HbA1c),fasting blood glucose (FBG),2 h postprandial blood glucose (2 h PBG),total cholesterol (TC),triglyceride (TG) and low density lipoprotein cholesterol (LDL-C),homocysteine (Hcy),and other indicators of change were compared,and the adverse reaction occurred was observated.Results 24 weeks after treatment,FBG,2 h PBG,HbA1c in the control group was (7.98±0.83) mmol/L,(12.25±0.90) mmol/L,and (8.05±1.05)%,respectively; the indexes in observation group were (7.09±0.80) mmol/L,(9.86±1.13) mmol/L and (7.01±0.88)%,respectively; FBG,2 h PBG,HbA1c in two groups were reduced compared with before treatment (P<0.05),those indexes in the observation group were significantly decreased compared with the control group (t=2.47,5.27,3.22,all P<0.05); 24 weeks after treatment,BMI,TC,TG,LDL-C,Hcy in the control were (27.60±3.70) kg/m2,(6.39±0.89) mmol/L,(2.77±0.40) mmol/L,(3.29±0.43) mmol/L and (17.4±2.03) mmol/L,respectively; those indexes in the observation group were (26.34±3.83) kg/m2,(5.31±0.72) mmol/L,(2.31±0.33) mmol/L,(2.92±0.44) mmol/L,(15.16±1.74) mmol/L,respectively; BMI,blood lipid,Hcy levels in the two groups were significantly decline compared with before treatment (P<0.05),those indexes in the observation group were significantly decreased compared with the control group (t=2.14,3.50,2.26,2.21,3.27,all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (χ2=2.62,P>0.05).Conclusion Vildagliptin combined with metformin can effectively control blood glucose and BMI of the obese or overweight patients with type 2 diabetes,and can improve the blood fat,lowering blood sugar,and not increase the risk of hypoglycemia,is one of effective treatments for overweight or obese patients with type 2 diabetes. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
